Zhejiang Chengyi Pharma

Zhejiang Chengyi Pharma is a leading Chinese pharmaceutical company focused on the development, manufacture, and commercialization of active pharmaceutical ingredients (APIs) and finished drug products. The company is globally recognized as a major producer of glucosamine hydrochloride, a key treatment for osteoarthritis and joint health. Beyond orthopedics, its diverse portfolio includes antiviral agents like ribavirin, immunosuppressants such as azathioprine, and cardiovascular medications. Chengyi Pharma operates state-of-the-art, GMP-certified manufacturing facilities in Zhejiang province and maintains a significant presence in both domestic and international markets. Listed on the Shanghai Stock Exchange, the company continues to expand its pipeline into high-value areas such as marine-derived medicines and specialized chemical generics.